NASDAQ:INKT
MiNK Therapeutics, Inc.
MiNK Therapeutics, Inc. reported net income of −$12.5M in fiscal 2025. The diluted share count rose 13.2%.Summary generated from MiNK Therapeutics, Inc.'s SEC filings. Latest annual report filed Mar 31, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equityn/a
Debt / equityn/a
Free cash flown/a
FCF marginn/a
Share count change+13.2%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | n/a | n/a | n/a |
| Operating income | −28 | −31 | −23 | −11 | −13 |
| Net income | −30 | −28 | −22 | −11 | −12 |
| Free cash flow | −13 | −19 | −16 | n/a | n/a |
Recent filings
- 4Insider transaction report
Sep 2, 2026 - 4Insider transaction report
Sep 2, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 13, 2026 - 8-KResults of operations and financial condition
Aug 13, 2026 - 8-KResults of a shareholder vote
Jun 23, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 15, 2026 - 8-KResults of operations and financial condition
May 15, 2026 - DEF 14AProxy statement
Apr 30, 2026